PRGO · Perrigo Company plc

This disposition represents a core execution milestone under Perrigo’s Three-S plan (Stabilize, Streamline, Strengthen), explicitly cited by CEO Patrick Lockwood-Taylor as advancing portfolio focus and sharpening emphasis on core self-care categories. The Dermacosmetics Business — comprising established brands ACO, Biodermal, Emolium, and Iwostin — contributed €120 million in net sales and approximately 5% of adjusted operating income in 2025, indicating it was a non-trivial but non-core revenue stream. Its exit supports Perrigo’s stated objective of enhancing financial flexibility: the €305.6 million in upfront proceeds (net of €5.6 million working capital adjustment) is designated primarily for debt reduction, directly strengthening the balance sheet. The contingent €27.0 million component introduces modest upside but carries execution risk tied entirely to the post-closing net sales performance of the divested business — a metric outside Perrigo’s control and not guaranteed. Strategic rationale centers on simplification: the business operated in Northern Europe, the Netherlands, and Poland, overlapping neither geographically nor operationally with Perrigo’s primary North America–focused OTC and store-brand model. With advisors Greenhill & Co. and Latham & Watkins engaged, the transaction reflects deliberate capital allocation discipline — exiting a lower-strategic-fit asset to reinforce core capabilities and reduce leverage, aligning with investor expectations for improved capital efficiency and margin clarity.